Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MACH-1 melanoma immunotherapy
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Epidermal
01
Overview
MACH-1 melanoma immunotherapy is a preclinical-stage nucleic acid-based therapeutic candidate developed by Orlance for the treatment of melanoma. The therapy utilizes the proprietary MACH-1 platform, a high-performance epidermal powdered gene gun (EPGG) delivery system. This technology delivers gold microparticles coated with nucleic acids (DNA or RNA) directly into the viable epidermis, specifically targeting antigen-presenting cells such as Langerhans cells. By delivering genetic material encoding melanoma-specific antigens directly into these cells, the immunotherapy is designed to elicit a robust and systemic T-cell mediated immune response to identify and destroy tumor cells. The program is currently in preclinical development.
- Other names
- Orlance melanoma immunotherapyMACH-1 epidermal powdered gene gun melanoma vaccineMACH1 epidermal powdered gene gun melanoma vaccineMACH 1 epidermal powdered gene gun melanoma vaccineMACH-1-Orlance-nucleic acid immunotherapy-epidermal-MelanomaMACH1-Orlance-nucleic acid immunotherapy-epidermal-MelanomaMACH 1-Orlance-nucleic acid immunotherapy-epidermal-Melanoma
02
Targets
GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on MACH-1 melanoma immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MACH-1 melanoma immunotherapy.